Today we announced the launch of Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases. Read more in the press release: https://lnkd.in/e6uFFjpa
关于我们
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.
- 网站
-
https://www.windwardbio.com
Windward Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股